Advent Said to Weigh Options Including $1.5 Billion BioDuro Sale

Buyout firm Advent International is considering options for its health-care company BioDuro-Sundia including a sale that could give the asset a value of at least $1.5 billion, according to people familiar with the matter.

Other options being evaluated with financial advisers include an initial public offering in China, the people said, asking not to be identified because the matter is confidential. Private equity firms and industry players could be interested in acquiring the drug research, development and manufacturing business, they said. A sale could even value BioDuro-Sundia at more than $2 billion, two of the people said.

Considerations are preliminary ...